The pandemic of the coronavirus disease 2019 (COVID-19) represents an unprecedented challenge to identify effective drugs for prevention and treatment. While the world’s attention is focused on news of COVID-19 vaccine updates, clinical management still requires improvement. Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected, clinicians need effective medical treatments for this infection.
【저자키워드】 COVID-19, Drug repurposing, vaccination, pandemic, Cancer, 【초록키워드】 Treatment, coronavirus disease, Inflammation, COVID-19 vaccine, clinical trial, Infection, medical treatment, anticancer drugs, Coagulopathy, Clinical management, Combination, immune dysfunction, similarity, Bicalutamide, clinician, Clinical data, while, effective, tested, identify, effective drug, 【제목키워드】 review, drug, clinical, Potential,